One of Double Bond Pharmaceuticals subsidiary, FarmPharma AB, has now launched its new, more modern website that gives more room for essential information about the company"s activities and actions.

"As our concern expands, it"s important that each subsidiary becomes more independent, and informative websites are the right step in this direction,” - Igor Lokot, CEO of Double Bond Pharmaceutical and Board director of FarmPharma comments. "Clear and transparent communication with the outside world and is the essence of how we work towards partners, customers and investors. We are excited to be able to grow organically and develop a lot in such a short period of time. "

More about FarmPharma: FarmPharma AB is a subsidiary of Double Bond Pharmaceutical. The company is active in the development and distribution of veterinary products, and their first product is for the prevention and treatment of bacterial and viral infections in cattle without the use of antibiotics. For more info: http://www.farmpharma.se/  

Video presentation: https://youtu.be/e1cPSC2PC70

For more info, contact
Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com 

Blog: http://blog.doublebp.com

Follow us on LinkedIn, Facebook and Twitter!

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.